Royalty Pharma (FRA:RPD) Short-Term Debt : €0 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Royalty Pharma Short-Term Debt?

Royalty Pharma's Short-Term Debt for the quarter that ended in Mar. 2024 was €0 Mil.

Royalty Pharma's annual Short-Term Debt increased from Dec. 2021 (€0 Mil) to Dec. 2022 (€942 Mil) but then declined from Dec. 2022 (€942 Mil) to Dec. 2023 (€0 Mil).

Royalty Pharma Short-Term Debt Historical Data

The historical data trend for Royalty Pharma's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Royalty Pharma Short-Term Debt Chart

Royalty Pharma Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

253.79

941.65

Royalty Pharma Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															932.54	922.42	-	-	-

Royalty Pharma Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Royalty Pharma Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Royalty Pharma's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Royalty Pharma (FRA:RPD) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Royalty Pharma PLC (FRA:RPD) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

RPRX:USA RPRX:Mexico RPD:Germany

Address

110 East 59th Street, FL 33, New York, NY, USA, 10022

Website

https://www.royaltypharma.com

Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.